In-House DMPK Transporter Assays vs. CRO Outsourcing: A Decision Framework
Running transporter assays in-house with commercial kits or sending compounds to a CRO — both have a place in a DMPK strategy. The right answer depends on your compound throughput, stage of development, data turnaround requirements, and whether you need regulatory-grade or exploratory data. This framework helps you decide.
The Core Trade-Off: Control vs. Convenience
The fundamental tension between in-house and outsourced DMPK testing is not simply cost — it is the trade-off between data ownership, turnaround speed, and the fixed investment required to build and maintain in-house capability. Neither model is universally better. Most organisations with active DMPK pipelines end up using a hybrid: in-house for early-stage screening, CRO for regulatory-grade confirmatory studies and specialist assays they do not run frequently enough to justify maintaining internally.
Head-to-Head Comparison
| Factor | In-House (Kit-Based) | CRO Outsourcing |
|---|---|---|
| Upfront cost | Moderate — kit purchase + initial assay setup | None — pay per study |
| Per-compound cost | Low once established — kit covers many runs | High — CRO FTE + overhead passed on |
| Turnaround time | 24–72 h (run when ready) | 2–6 weeks (queue + report) |
| Data ownership | Full — raw data in-house | CRO holds raw data; you receive report |
| Flexibility to re-test / iterate | High — re-run on same day | Requires new study order + wait time |
| Assay validation status | Depends on kit and internal SOP quality | Typically fully validated, GLP-compliant available |
| Regulatory acceptance | Requires in-house validation data; may need independent confirmation | CRO regulatory reports accepted by FDA, EMA |
| Am besten geeignet für | Early discovery screening, structure-activity series, high-throughput triage | IND/NDA regulatory package, specialist assays (BSEP IC50, ciPTEC DDI), confirmatory studies |
When to Run In-House
Early-phase compound triage (discovery to lead optimisation)
In discovery, you may be screening dozens of analogues per week across a transporter panel. CRO turnaround times of 2–6 weeks are incompatible with the pace of medicinal chemistry iteration. In-house vesicle kits allow same-week readouts for P-gp, BCRP, BSEP, and MRP inhibition screening — enabling rapid structure-activity data that can inform the next round of synthesis before the chemistry team has even synthesised the next batch.
Routine profiling of an active chemical series
Once you have a validated in-house assay for a specific transporter (e.g. P-gp inhibition using an ABCB1 vesicle kit), running the same assay repeatedly across a series is cost-efficient and straightforward. The marginal cost of running an additional compound through an established in-house assay is the kit reagent cost — typically a fraction of a CRO invoice.
Data confidentiality requirements
Some sponsors, particularly in competitive pipeline areas, prefer to keep compound identity and structure data in-house for as long as possible. Running transporter screening internally eliminates the need to disclose compound structures to a CRO until a later, more protected stage of development.
Renal transporter profiling with ciPTEC
For organisations that run regular renal DDI studies, maintaining an in-house ciPTEC cell culture for OAT1, OAT3, OCT2, MATE1 and MATE2-K substrate and inhibition assays provides significant throughput advantages over CRO outsourcing — particularly for iterative series profiling. ciPTEC cell lines from Cell4Pharma are available for in-house culture establishment in DACH through SeamlessBio.
When to Use a CRO
Regulatory-grade confirmatory studies (IND, NDA, IMPD)
Regulatory submissions require transporter DDI data generated under GLP or with assay validation documentation meeting FDA/EMA/ICH M12 standards. Most pharma companies outsource the definitive regulatory package to a CRO — even if initial screening was conducted in-house — to obtain a GLP-compliant, independently auditable study report. The CRO provides a validation dossier that becomes part of the submission package.
Assays you do not run frequently enough to justify internal investment
Specialist assays — for example, BSEP IC50 dose-response with a radiolabelled substrate, or a comprehensive ciPTEC DDI panel — require significant expertise and equipment investment to run reproducibly. If you encounter these once or twice per year, outsourcing is more cost-effective than maintaining the internal capability. SeamlessBio also offers a DMPK assay service for ciPTEC-based transporter studies, which bridges the gap between full in-house setup and full CRO dependency.
Capacity overflow during peak development periods
Even fully equipped in-house DMPK groups use CROs to absorb peak demand when multiple compounds are advancing simultaneously. A CRO panel can run in parallel with your in-house queue without displacing other project work.
The Hybrid Model: How Most DMPK Groups Actually Operate
In-House Transporter Kits — Ready to Order in DACH
Cell4Pharma ABC transporter vesicle kits (P-gp, BCRP, BSEP, MRP1–5, MRP8) and ciPTEC renal cell lines — distributed exclusively in DACH by SeamlessBio. Free test sample available. Full technical support included.
View DMPK Kit Portfolio Request a Free Test Sample
English 
Deutsch